Q3 2026
Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001999371-26-025220
What the release said
Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2026.
Solésence reported third quarter 2026 revenue of $20.2 million, compared to $14.6 million for the same period in 2025, and a gross margin of 39.3%, compared to 23.8%.¶2¶3
The CEO said the company completed the primary investment and implementation phase of its first pillar, operational excellence, in the third quarter.¶4
- Third quarter 2026 revenue
- $20.2 million Compared to $14.6 million for the same period in 2025¶2
- Third quarter 2026 net income
- $3.7 million Compared to a net loss of $1.0 million for the same period in 2025¶5
- Third quarter 2026 gross profit
- $7.9 million Compared to $3.5 million for the same period in 2025¶6
- Third quarter 2026 gross margin
- 39.3% Compared to 23.8% for the same period in 2025¶3
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $20.16M | $14.60M | $16.87M | $7.96M |
| Net Income | $3.67M | -$1.02M | $2.72M | -$1.44M |
| EPS Diluted | $0.05 | -$0.01 | $0.04 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Solesence, Inc. · CIK 883107 · Engraved from SEC EDGAR